Guidance for anti-VEGF intravitreal injections during the COVID-19 pandemic
Purpose There is an urgent need to address how to best provide ophthalmic care for patients with retinal disease receiving intravitreal injections with anti-vascular endothelial growth factor agents during the ongoing global COVID-19 pandemic. This article provides guidance for ophthalmologists on h...
- Autores:
- Tipo de recurso:
- Fecha de publicación:
- 2020
- Institución:
- Universidad del Rosario
- Repositorio:
- Repositorio EdocUR - U. Rosario
- Idioma:
- eng
- OAI Identifier:
- oai:repository.urosario.edu.co:10336/24776
- Acceso en línea:
- https://doi.org/10.1007/s00417-020-04703-x
https://repository.urosario.edu.co/handle/10336/24776
- Palabra clave:
- Retinal disease
Ophthalmology
COVID-19
Coronavirus
Recommendations
Vision Academy
- Rights
- License
- Abierto (Texto Completo)
id |
EDOCUR2_31c5a92e13a0452f79436a4f25991292 |
---|---|
oai_identifier_str |
oai:repository.urosario.edu.co:10336/24776 |
network_acronym_str |
EDOCUR2 |
network_name_str |
Repositorio EdocUR - U. Rosario |
repository_id_str |
|
dc.title.spa.fl_str_mv |
Guidance for anti-VEGF intravitreal injections during the COVID-19 pandemic |
title |
Guidance for anti-VEGF intravitreal injections during the COVID-19 pandemic |
spellingShingle |
Guidance for anti-VEGF intravitreal injections during the COVID-19 pandemic Retinal disease Ophthalmology COVID-19 Coronavirus Recommendations Vision Academy |
title_short |
Guidance for anti-VEGF intravitreal injections during the COVID-19 pandemic |
title_full |
Guidance for anti-VEGF intravitreal injections during the COVID-19 pandemic |
title_fullStr |
Guidance for anti-VEGF intravitreal injections during the COVID-19 pandemic |
title_full_unstemmed |
Guidance for anti-VEGF intravitreal injections during the COVID-19 pandemic |
title_sort |
Guidance for anti-VEGF intravitreal injections during the COVID-19 pandemic |
dc.subject.keyword.spa.fl_str_mv |
Retinal disease Ophthalmology COVID-19 Coronavirus Recommendations Vision Academy |
topic |
Retinal disease Ophthalmology COVID-19 Coronavirus Recommendations Vision Academy |
description |
Purpose There is an urgent need to address how to best provide ophthalmic care for patients with retinal disease receiving intravitreal injections with anti-vascular endothelial growth factor agents during the ongoing global COVID-19 pandemic. This article provides guidance for ophthalmologists on how to deliver the best possible care for patients while minimizing the risk of infection. Methods The Vision Academy's Steering Committee of international retinal disease experts convened to discuss key considerations for managing patients with retinal disease during the COVID-19 pandemic. After reviewing the existing literature on the issue, members put forward recommendations that were systematically refined and voted on to develop this guidance. Results The considerations focus on the implementation of steps to minimize the exposure of patients and healthcare staff to COVID-19. These include the use of personal protective equipment, adherence to scrupulous hygiene and disinfection protocols, pre-screening to identify symptomatic patients, and reducing the number of people in waiting rooms. Other important measures include triaging of patients to identify those at the greatest risk of irreversible vision loss and prioritization of treatment visits over monitoring visits where possible. In order to limit patient exposure, ophthalmologists should refrain from using treatment regimens that require frequent monitoring. Conclusion Management of patients with retinal disease receiving intravitreal injections during the COVID-19 pandemic will require adjustment to regular clinical practice to minimize the risk of exposure of patients and healthcare staff, and to prioritize those with the greatest medical need. The safety of patients and healthcare staff should be of paramount importance in all decision-making. |
publishDate |
2020 |
dc.date.accessioned.none.fl_str_mv |
2020-06-11T13:21:13Z |
dc.date.available.none.fl_str_mv |
2020-06-11T13:21:13Z |
dc.date.created.spa.fl_str_mv |
2020-04-23 |
dc.type.eng.fl_str_mv |
article |
dc.type.coarversion.fl_str_mv |
http://purl.org/coar/version/c_970fb48d4fbd8a85 |
dc.type.coar.fl_str_mv |
http://purl.org/coar/resource_type/c_6501 |
dc.type.spa.spa.fl_str_mv |
Artículo |
dc.identifier.doi.none.fl_str_mv |
https://doi.org/10.1007/s00417-020-04703-x |
dc.identifier.issn.none.fl_str_mv |
0721-832X 1435-702X |
dc.identifier.uri.none.fl_str_mv |
https://repository.urosario.edu.co/handle/10336/24776 |
url |
https://doi.org/10.1007/s00417-020-04703-x https://repository.urosario.edu.co/handle/10336/24776 |
identifier_str_mv |
0721-832X 1435-702X |
dc.language.iso.none.fl_str_mv |
eng |
language |
eng |
dc.relation.citationEndPage.none.fl_str_mv |
8 |
dc.relation.citationStartPage.none.fl_str_mv |
1 |
dc.relation.citationTitle.none.fl_str_mv |
Graefe`s Archive for Clinical and Experimental Ophthalmology |
dc.relation.ispartof.spa.fl_str_mv |
Graefe's Archive for Clinical and Experimental Ophthalmology, ISSN: 0721-832X;1435-702X, No. (2020-04-23); pp. 1-8 |
dc.relation.uri.spa.fl_str_mv |
https://link.springer.com/content/pdf/10.1007/s00417-020-04703-x.pdf |
dc.rights.coar.fl_str_mv |
http://purl.org/coar/access_right/c_abf2 |
dc.rights.acceso.spa.fl_str_mv |
Abierto (Texto Completo) |
rights_invalid_str_mv |
Abierto (Texto Completo) http://purl.org/coar/access_right/c_abf2 |
dc.format.mimetype.none.fl_str_mv |
application/pdf |
dc.publisher.spa.fl_str_mv |
Graefe's Archive for Clinical and Experimental Ophthalmology |
institution |
Universidad del Rosario |
dc.source.instname.spa.fl_str_mv |
instname:Universidad del Rosario |
dc.source.reponame.spa.fl_str_mv |
reponame:Repositorio Institucional EdocUR |
bitstream.url.fl_str_mv |
https://repository.urosario.edu.co/bitstreams/093bcab5-eedd-47fe-a818-fe24e531c27b/download https://repository.urosario.edu.co/bitstreams/fafec991-9163-4a91-bcce-5765b752a819/download https://repository.urosario.edu.co/bitstreams/74db41a6-cca4-4267-b1e7-15c71683405c/download |
bitstream.checksum.fl_str_mv |
14dba7c1b699ff6304de93cf35a229a5 17dcf5c17f9fde4ac9e66d19d6f15f22 008b5ea1f8fa97c14f936ea60691bd5b |
bitstream.checksumAlgorithm.fl_str_mv |
MD5 MD5 MD5 |
repository.name.fl_str_mv |
Repositorio institucional EdocUR |
repository.mail.fl_str_mv |
edocur@urosario.edu.co |
_version_ |
1818106528249413632 |
spelling |
8b521d7e-5e5e-4b4a-bab5-168bdb189eb0-16f15a7e9-21b9-4a10-bf18-07de8b648e9a-11bc9b933-7d8c-4bde-bba7-e251c6c33e0b-183353ab2-f2d2-400b-a407-3f26b6ed2bb8-1b21c4f8f-b9ab-4a07-a97d-65b60982da34-19a0f36dd-55c1-4175-bbdc-bbd55b4cbaf4-19e2973d5-6b0c-4568-b949-214b690498b7-123f32c73-f71c-415b-b229-a7ea64605d19-19c2f9029-f72d-4a62-8c52-82fafe0b5c10-1c5eb83f7-7c14-4c82-b057-7c9a6950de14-1799c21f0-641d-43c1-9912-c7a55210fdb5-1e27c1a08-d48c-4f4c-8598-a7691846e08a-146cf489a-6cbe-4d89-b5b9-26afc9eca194-160495f22-0781-479b-9969-803d572bdbbf-1e9382a84-7532-4238-a6e9-d0b1e9cc130f-12020-06-11T13:21:13Z2020-06-11T13:21:13Z2020-04-23Purpose There is an urgent need to address how to best provide ophthalmic care for patients with retinal disease receiving intravitreal injections with anti-vascular endothelial growth factor agents during the ongoing global COVID-19 pandemic. This article provides guidance for ophthalmologists on how to deliver the best possible care for patients while minimizing the risk of infection. Methods The Vision Academy's Steering Committee of international retinal disease experts convened to discuss key considerations for managing patients with retinal disease during the COVID-19 pandemic. After reviewing the existing literature on the issue, members put forward recommendations that were systematically refined and voted on to develop this guidance. Results The considerations focus on the implementation of steps to minimize the exposure of patients and healthcare staff to COVID-19. These include the use of personal protective equipment, adherence to scrupulous hygiene and disinfection protocols, pre-screening to identify symptomatic patients, and reducing the number of people in waiting rooms. Other important measures include triaging of patients to identify those at the greatest risk of irreversible vision loss and prioritization of treatment visits over monitoring visits where possible. In order to limit patient exposure, ophthalmologists should refrain from using treatment regimens that require frequent monitoring. Conclusion Management of patients with retinal disease receiving intravitreal injections during the COVID-19 pandemic will require adjustment to regular clinical practice to minimize the risk of exposure of patients and healthcare staff, and to prioritize those with the greatest medical need. The safety of patients and healthcare staff should be of paramount importance in all decision-making.application/pdfhttps://doi.org/10.1007/s00417-020-04703-x0721-832X1435-702Xhttps://repository.urosario.edu.co/handle/10336/24776engGraefe's Archive for Clinical and Experimental Ophthalmology81Graefe`s Archive for Clinical and Experimental OphthalmologyGraefe's Archive for Clinical and Experimental Ophthalmology, ISSN: 0721-832X;1435-702X, No. (2020-04-23); pp. 1-8https://link.springer.com/content/pdf/10.1007/s00417-020-04703-x.pdfAbierto (Texto Completo)http://purl.org/coar/access_right/c_abf2instname:Universidad del Rosarioreponame:Repositorio Institucional EdocURRetinal diseaseOphthalmologyCOVID-19CoronavirusRecommendationsVision AcademyGuidance for anti-VEGF intravitreal injections during the COVID-19 pandemicarticleArtículohttp://purl.org/coar/version/c_970fb48d4fbd8a85http://purl.org/coar/resource_type/c_6501Korobelnik, Jean-FrançoisLoewenstein, AnatEldem, BoraJoussen, Antonia M.Koh, AdrianLambrou, George N.Lanzetta, PaoloLi, XiaoxinLövestam-Adrian, MonicaNavarro, RafaelOkada, Annabelle A.Pearce, IanRodríguez, Francisco J.Wong, David T.Wu, LihtehORIGINALKorobelnik2020_Article_GuidanceForAnti-VEGFIntravitre.pdfapplication/pdf388739https://repository.urosario.edu.co/bitstreams/093bcab5-eedd-47fe-a818-fe24e531c27b/download14dba7c1b699ff6304de93cf35a229a5MD51TEXTKorobelnik2020_Article_GuidanceForAnti-VEGFIntravitre.pdf.txtKorobelnik2020_Article_GuidanceForAnti-VEGFIntravitre.pdf.txtExtracted texttext/plain39045https://repository.urosario.edu.co/bitstreams/fafec991-9163-4a91-bcce-5765b752a819/download17dcf5c17f9fde4ac9e66d19d6f15f22MD52THUMBNAILKorobelnik2020_Article_GuidanceForAnti-VEGFIntravitre.pdf.jpgKorobelnik2020_Article_GuidanceForAnti-VEGFIntravitre.pdf.jpgGenerated Thumbnailimage/jpeg4527https://repository.urosario.edu.co/bitstreams/74db41a6-cca4-4267-b1e7-15c71683405c/download008b5ea1f8fa97c14f936ea60691bd5bMD5310336/24776oai:repository.urosario.edu.co:10336/247762021-06-03 00:50:35.014https://repository.urosario.edu.coRepositorio institucional EdocURedocur@urosario.edu.co |